News - Esbriet

Filter

Current filters:

Esbriet

Popular Filters

Ireland's HSE to reimburse InterMune's Esbriet for IPF

08-07-2013

US biotech firm InterMune's (Nasdaq: ITMN) UK subsidiary says that Ireland's Health Service Executive…

BiotechnologyEsbrietEuropeInterMunePricingRegulationRespiratory and Pulmonary

Pricing and reimbursement conditions for InterMune's Esbriet in Italy

17-06-2013

US biotech firm InterMune (Nasdaq: ITMN) says that the board of the Italian Drug Agency (AIFA) has approved…

BiotechnologyEsbrietEuropeInterMunePricingRespiratory and Pulmonary

New idiopathic pulmonary fibrosis treatment may open up valuable research opportunity, says GlobalData

17-04-2013

Further research is a prerequisite to shine a light on idiopathic pulmonary fibrosis (IPF) and offer…

BiotechnologyEsbrietInterMunePricingRare diseasesRegulationResearch

Positive NICE news for GSK's Revolade and InterMune's Esbriet

21-03-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence today (March 21) issued two…

BiotechnologyEsbrietEuropeGlaxoSmithKlineImmunologicalsInterMunePharmaceuticalPricingRegulationRespiratory and PulmonaryRevolade

UK pharma group slams NICE for failing to recognize nature of discovery and development

07-12-2012

The Association of the British Pharmaceutical Industry (ABPI) yesterday expressed major concern on behalf…

EsbrietEuropeInterMunePharmaceuticalPricingRegulation

UK's NICE initially negative on InterMune's Esbriet for idiopathic pulmonary fibrosis

30-11-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) said yesterday that…

BiotechnologyEsbrietEuropeInterMunePricingRegulationRespiratory and Pulmonary

French price regulator authorizes reimbursement of InterMune's Esbriet

12-09-2012

USA-based InterMune (Nasdaq: ITMN) says that French regulator the Comite Economique des Produits de…

EsbrietEuropeInterMunePharmaceuticalPricingRespiratory and Pulmonary

InterMune to divest Actimmune for $55 million; to focus on Esbriet

22-05-2012

California, USA-based biotech firm InterMune (Nasdaq: ITMN) says that it has reached a definitive agreement…

ActimmuneBiotechnologyEsbrietFinancialImmunologicalsInterMuneMergers & AcquisitionsRespiratory and PulmonaryVidara Therapeutics

French Transparency Commission issues favorable opinion on Esbriet

10-04-2012

There was good news last week for USA-based InterMune (Nasdaq: ITMN) when the Transparency Commission…

EsbrietEuropeInterMunePharmaceuticalPricingRegulationRespiratory and Pulmonary

Esbriet offers additional benefit, says German G-BA

16-03-2012

USA-based InterMune (Nasdaq: ITMN) says that the German Federal Joint Committee (G-BA) has announced…

EsbrietEuropeInterMunePharmaceuticalPricingRegulationRespiratory and Pulmonary

Germany’s IQWIG negative on InterMune’s Esbriet

18-12-2011

US biotech firm InterMune (Nasdaq: ITMN) says that Germany’s private Institute for Quality and Efficiency…

BiotechnologyEsbrietEuropeInterMuneRare diseasesRegulationRespiratory and Pulmonary

InterMune’s IPF drug Esbriet sees first European launch, in Germany

13-09-2011

US biotech firm InterMune (Nasdaq: ITMN) has announced that Esbriet (pirfenidone) will be offered to…

BiotechnologyEsbrietEuropeInterMuneMarkets & MarketingPharmaceuticalRespiratory and Pulmonary

Back to top